德康医疗Connect研究显示：G7与多种药物联合使用可显著降低糖化血红蛋白

美股速递06-07

德康医疗的Connect研究数据表明，当将其G7持续血糖监测系统与包括二甲双胍、GLP-1受体激动剂及SGLT2抑制剂在内的多种药物组合方案联用时，能够实现具有临床意义的糖化血红蛋白降低。这项发现突显了整合先进监测技术与多元化药物治疗在糖尿病管理中的协同潜力，为优化患者血糖控制提供了新的循证依据。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1139993429?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-07 02:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139993429","market":"us","top_or_hot":-1,"title":"德康医疗Connect研究显示：G7与多种药物联合使用可显著降低糖化血红蛋白","media":"美股速递","content":"<p>德康医疗的Connect研究数据表明，当将其G7持续血糖监测系统与包括二甲双胍、GLP-1受体激动剂及SGLT2抑制剂在内的多种药物组合方案联用时，能够实现具有临床意义的糖化血红蛋白降低。\n这项发现突显了整合先进监测技术与多元化药物治疗在糖尿病管理中的协同潜力，为优化患者血糖控制提供了新的循证依据。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>德康医疗Connect研究显示：G7与多种药物联合使用可显著降低糖化血红蛋白</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n德康医疗Connect研究显示：G7与多种药物联合使用可显著降低糖化血红蛋白\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-07 02:45 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>德康医疗的Connect研究数据表明，当将其G7持续血糖监测系统与包括二甲双胍、GLP-1受体激动剂及SGLT2抑制剂在内的多种药物组合方案联用时，能够实现具有临床意义的糖化血红蛋白降低。\n这项发现突显了整合先进监测技术与多元化药物治疗在糖尿病管理中的协同潜力，为优化患者血糖控制提供了新的循证依据。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"","article_id":"1139993429","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139993429","pubTimestamp":1780771518,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"德康医疗的Connect研究数据表明，当将其G7持续血糖监测系统与包括二甲双胍、GLP-1受体激动剂及SGLT2抑制剂在内的多种药物组合方案联用时，能够实现具有临床意义的糖化血红蛋白降低。\n这项发现突显了整合先进监测技术与多元化药物治疗在糖尿病管理中的协同潜力，为优化患者血糖控制提供了新的循证依据。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","BK4082":"医疗保健设备","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BK4504":"桥水持仓","BK4588":"碎股","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","BK4548":"巴美列捷福持仓","DXCM":"德康医疗","BK4551":"寇图资本持仓","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD"},"translate_title":"Dekang Medical Connect study shows that G7 can significantly reduce glycosylated hemoglobin when used in combination with multiple drugs","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXCM":1},"content_text":"德康医疗的Connect研究数据表明，当将其G7持续血糖监测系统与包括二甲双胍、GLP-1受体激动剂及SGLT2抑制剂在内的多种药物组合方案联用时，能够实现具有临床意义的糖化血红蛋白降低。\n这项发现突显了整合先进监测技术与多元化药物治疗在糖尿病管理中的协同潜力，为优化患者血糖控制提供了新的循证依据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139993429","isCrawlerRequest":true}